GlassScriptPhysician profile
Shrutika Vasudeva
NPI 1053669127
$1,507.99
in general payments reported to CMS, 2019-2025
25 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $195 · 2021: $195 · 2022: $258 · 2023: $232 · 2024: $217 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $214.91 | 2019-2024 | Prolia, Evenity |
| Abbvie INC. | $210.36 | 2019-2023 | Liletta |
| Exeltis, USA INC. | $115.89 | 2021-2024 | Slynd |
| Astellas Pharma US INC | $101.38 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $93.92 | 2019-2025 | Myosure Tissue Removal Device, Aptima |
| Mayne Pharma Commercial LLC | $81.17 | 2022-2025 | |
| Renovia INC | $72.98 | 2021 | |
| Sage Therapeutics, LLC | $68.88 | 2025 | Zurzuvae |
| Medtronic, INC. | $64.19 | 2024 | V-Loc 180 |
| Bayer Healthcare Pharmaceuticals INC. | $63.03 | 2020-2023 | |
| Coopersurgical, INC. | $44.98 | 2020-2025 | Paragard T 380a, Summit Doppler |
| Exact Sciences Corporation | $43.39 | 2023-2024 | Cologuard Collection Kit |
| Millicent US INC | $42.84 | 2023-2025 | Femlyv, Intrarosa, Femring |
| Avion Pharmaceuticals | $40.95 | 2019-2022 | |
| Axonics, INC. | $35.30 | 2023 | Axonics |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $34.75 | 2020 | |
| Pfizer INC. | $33.31 | 2020-2022 | |
| Scynexis, INC. | $31.85 | 2022 | |
| Gilead Sciences, INC. | $27.10 | 2019 | |
| Sumitomo Pharma America, INC. | $17.68 | 2025 | Myfembree |
| Myovant Sciences INC. | $16.18 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.03 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $14.27 | 2021 | |
| Merck Sharp & Dohme LLC | $13.14 | 2019 | |
| Aspira Women'S Health INC | $10.51 | 2023 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrutika Vasudeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.